APA

D'Adda M., Farina M., Schieppati F., Borlenghi E., Bottelli C., Cerqui E., Ferrari S., Gramegna D., Pagani C., Passi A., Maifredi A., Tucci A., Capucci M. A., Ruggeri G. & Rossi G. (20200211). The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. : Cancer.

Chicago

D'Adda Mariella, Farina Mirko, Schieppati Francesca, Borlenghi Erika, Bottelli Chiara, Cerqui Elisa, Ferrari Samantha, Gramegna Doriana, Pagani Chiara, Passi Angela, Maifredi Adriana, Tucci Alessandra, Capucci Maria A, Ruggeri Giuseppina and Rossi Giuseppe. 20200211. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. : Cancer.

Harvard

D'Adda M., Farina M., Schieppati F., Borlenghi E., Bottelli C., Cerqui E., Ferrari S., Gramegna D., Pagani C., Passi A., Maifredi A., Tucci A., Capucci M. A., Ruggeri G. and Rossi G. (20200211). The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. : Cancer.

MLA

D'Adda Mariella, Farina Mirko, Schieppati Francesca, Borlenghi Erika, Bottelli Chiara, Cerqui Elisa, Ferrari Samantha, Gramegna Doriana, Pagani Chiara, Passi Angela, Maifredi Adriana, Tucci Alessandra, Capucci Maria A, Ruggeri Giuseppina and Rossi Giuseppe. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. : Cancer. 20200211.